García H, Díaz R, Pablo Barés J, Nevah E, Fábrega J M
Servicio de Riesgo Profesional, Centro Médico Paitilla y en el Hospital de la Caja de Seguro Social.
Rev Med Panama. 1994 Jan;19(1):8-12.
A significant number of oncology patients need intravenous chemotherapy. Peripheral venous access is generally difficult, frequently requiring central venous access. This study reviews the Author's experience with permanent venous portals. A total of 66 patients records, from January 1992 to April 1994, were reviewed. The central venous portals remained in place an average of 272 days. An average of 8 courses of chemotherapy were given through each port. There was no significant difference in the rate of complications secondary to the portal site. The Authors conclude that the placement of permanent venous portals is a safe and reliable chronic venous access in patients with cancer who require intravenous therapy. The rate of serious complication was 3% which is relatively low for these immunosuppressed patients. All venous portals, except one (98.5%) remained functional.
相当数量的肿瘤患者需要静脉化疗。外周静脉通路通常难以建立,常常需要中心静脉通路。本研究回顾了作者使用永久性静脉端口的经验。回顾了1992年1月至1994年4月期间共66例患者的记录。中心静脉端口平均留置272天。每个端口平均进行8个疗程的化疗。端口部位继发并发症的发生率无显著差异。作者得出结论,对于需要静脉治疗的癌症患者,永久性静脉端口的置入是一种安全可靠的慢性静脉通路。严重并发症发生率为3%,对于这些免疫抑制患者来说相对较低。除一个端口外(98.5%),所有静脉端口均保持功能正常。